Assessment of Egg Nutrient Compositional Changes and Residue in Eggs, Tissues, and Excreta Following Oral Administration of Atorvastatin to Laying Hens
Authors:
- 29 April 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 51 (11) , 3473-3481
Abstract
Laying hens were fed a control diet alone or with 0.06 g of atorvastatin, a synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, per 100 g of diet for 20 days. Compared to controls, egg yolks from treated hens contained greater amounts of amino acids and reduced levels of total fatty acids and cholesterol. In contrast, egg albumen amino acid contents were unaffected by dietary treatments. In a residue study, seven hens each received a single oral dose of ∼20 μCi of [14C]atorvastatin. Approximately 71% of the radioactivity was recovered in the excreta and liver, whereas virtually no radioactivity was detected in kidney, heart, muscle, bile, plasma, or egg albumen at 15 days postdosing. Yolk radioactivity peaked at 4 days postdosing in six of the seven birds and was absent in eggs laid after day 10. Reminiscent of that of certain antibiotic drugs, the atorvastatin egg residue pattern appeared to coincide with the physiological pattern of daily yolk accretion within the ovary. Keywords: Atorvastatin; drug residues; egg nutrient composition; laying hensKeywords
This publication has 19 references indexed in Scilit:
- Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.The American Journal of Cardiology, 2001
- NK-104: a novel synthetic HMG-CoA reductase inhibitorExpert Opinion on Investigational Drugs, 2000
- The Impact of Egg Limitations on Coronary Heart Disease Risk: Do the Numbers Add Up?Journal of the American College of Nutrition, 2000
- Coronary Heart Disease: Reducing The RiskCirculation, 1999
- Alteration of egg yolk cholesterol content and plasma lipoprotein profiles following administration of a totally synthetic HMG-CoA reductase inhibitor to laying hensJournal of Agricultural and Food Chemistry, 1993
- Effect ofβ, β’‐tetramethyl‐substituted hexadecanedioic acid (medica 16) on laying hen performance and egg yolk lipid compositionBritish Poultry Science, 1992
- Reduction of the cholesterol content of eggs by the oral administration of lovastatin to laying hensJournal of Agricultural and Food Chemistry, 1990
- Regulation of the mevalonate pathwayNature, 1990
- Modifying egg yolk cholesterol in the domestic fowl—a reviewWorld's Poultry Science Journal, 1988
- Heterogeneity of cholesterol homeostasis in man. Response to changes in dietary fat quality and cholesterol quantity.Journal of Clinical Investigation, 1987